NeoProgen, a Baltimore-based company led by medtech entrepreneur Bill Niland, raised $1.5 million in seed funding as it develops a cell therapy for patients following a heart attack.
The round featured an all-Maryland lineup of investors: The University System of Maryland’s Momentum Fund, which contributed $245,000; TEDCO; and UM Ventures, which is the commercialization arm of the University of Maryland.
Like his earlier venture, Harpoon Medical, NeoProgen h
{iframe}https://biobuzz.inloop.com/en/article/75231?utm_source=ElasticEmail-sb-biobizHub&utm_medium=newsletter&utm_campaign=biobizHub-672-s-en-231019&itd_did=672&itd_uid=3432{/iframe}